In the News

October 2, 2019
The Biosimilars Council applauds bipartisan efforts in the U.S. House of Representatives that would encourage biosimilar uptake and utilization by patients in the Medicare program by aligning patient, provider and taxpayer incentives.
September 17, 2019
Dear Chairman Alexander and Ranking Member Murray: On behalf of the undersigned organizations, we write to express urgent concern about a proposal in the President’s budget request that would undermine trust in the quality of biologic medicines.
September 9, 2019
The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), today released Part II of its white paper series, “Failure to Launch,” finding that anti-competitive rebating tactics by brand-name manufacturers, coupled with policy failures and inadequate incentives for biosimilar use, stifle biosimilars adoption in the United States.
August 26, 2019
A coalition of over twenty stakeholders, including the American Cancer Society Cancer Action Network, CVS Health and USP submitted a letter to U.S. Health and Human Services Secretary Azar encouraging the use of biosimilars across Medicare programs.
June 25, 2019
Patent “thicketing” occurs when a brand-name pharmaceutical company accumulates dozens of patents near the end of the product lifecycle under the guise of “innovative” processes or development that warrant additional protections
May 30, 2019
UnitedHealthcare’s (UHC) recent announcement that it will begin preferring brand name biologics over lower priced FDA-approved biosimilars is a step backwards in patient care.

Want to keep up to date with the biosimilars industry?

Sign up for Biosimilars Council Newsletter to hear about the field, learn about events, and find out how you can make an impact.